SCHEMBL3809268

SCHEMBL3809268

CN(Cc1ccc(C(=O)NC2C3CC4CC(C3)CC2C4)cc1)S(C)(=O)=O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.49
ALDH1A1 P00352 3/20 0.47
MAPT P10636 3/20 0.47
HDAC6 Q9UBN7 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPK1 P28482 1/20 0.45
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.44
HSD11B1 P28845 3/20 0.43
EPHX2 P34913 2/20 0.43
HTT P42858 2/20 0.43
HDAC1 Q13547 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14532093 0.83 CYP3A4 (0.56) CYP3A4ALDH1A1MAPTHDAC6MEN1
SCHEMBL3809265 0.78 L3MBTL1 (0.45) CYP3A4ALDH1A1MAPTHDAC6L3MBTL1
SCHEMBL3809081 0.77 EPHX2 (0.51) HDAC6L3MBTL1MEN1KMT2ACNR1
SCHEMBL4608538 0.76 KMT2A (0.54) HDAC6L3MBTL1MEN1KMT2ACNR1
SCHEMBL3815299 0.76 KMT2A (0.46) HDAC6L3MBTL1MEN1KMT2ACNR1
SCHEMBL3811363 0.75 HDAC6 (0.41) HDAC6L3MBTL1MEN1KMT2AHSD11B1
SCHEMBL3811389 0.74 L3MBTL1 (0.40) CYP3A4HDAC6L3MBTL1MEN1KMT2A
SCHEMBL13838923 0.74 CNR2 (0.52) ALDH1A1MAPTHDAC6L3MBTL1MEN1
SCHEMBL3809079 0.74 HSD11B1 (0.51) HDAC6L3MBTL1MEN1KMT2AHSD11B1
SCHEMBL13838908 0.74 HDAC6 (0.46) ALDH1A1HDAC6L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US claimed
EP-1948190-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2008-07-30 EP claimed
WO-2007051810-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2007-05-10 WO claimed
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US disclosed
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US disclosed
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US disclosed
EP-1948190-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2008-07-30 EP disclosed
WO-2007051810-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HSD11B1, HSD11B2, HSD3B1 CYP3A4 88/4885ALDH1A1 220/4885MAPT 3707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.